Best Traditional Pharmaceuticals Companies in United Kingdom
The 78 best Traditional Pharmaceuticals companies in United Kingdom in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: SynOx.
- HTF Market Intelligence
- Coherent Market Insights
Our analysis of 50 Traditional Pharmaceuticals companies
$3.2b in tracked funding; 51% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2016.
Ranked: Best Traditional Pharmaceuticals companies in United Kingdom
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SynOx Manufacturer of drugs | $136M | 19 mo ago | Series B | — | 2020 | WordPressMySQLPHP+17 | — | — |
| 2 | Archimedes Pharma Developer of generic pharmaceuticals | $100M | 195 mo ago | Acquired | Jeffrey Buchalter ex-CEO | 2004 | — | — | — |
| 3 | Speciality European Pharma Developer of medicines for urological conditions | $49M | 121 mo ago | Acquired | — | 2006 | — | — | — |
| 4 | Alliance International consumer healthcare business managing brands and partnerships | $45M | 96 mo ago | Public | Peter Butterfield CEO | 1998 | AzureCloudflarejQuery+7 | 15 patents Food processing (chocolate formulation) and financial trading/liquidity management software platforms. | — |
| 5 | Quantum Pharmaceutical Manufacturer of unlicensed medicines | $18M | 116 mo ago | Acquired | — | 2004 | WordPressMySQLPHP+27 | — | 1 job opening |
| 6 | Quantum Pharma Group Manufacturer of drugs | $18M | 116 mo ago | Acquired | Andrew Matthews CEO & MD | 2004 | — | — | — |
| 7 | Gelemetix Provider of non-invasive alternatives to surgery non-invasive alternatives to surgery for chronic low back… | $12M | 61 mo ago | Series C | — | 2012 | — | — | — |
| 8 | Syntropharma Provider of UK holiday park accommodations and ownership opportunities | $5M | 198 mo ago | Series A | Andrew Gardiner CEO | 2005 | — | — | — |
| 9 | Focus Pharmaceuticals Provider of geospatial data and aerial imagery services | $4M | — | Acquired | Mark Cresswell CEO & MD | 2002 | — | — | — |
| 10 | Ridge Pharma Marketer of branded prescription medicines for unmet needs | $4M | 93 mo ago | Series A | — | 2017 | WordPressMySQLSalesforce+16 | — | — |
| 11 | Intrapharm Labs OTC products manufacturer and supplier | $3M | 140 mo ago | Acquired | Kevin James CEO & Chairman | 1999 | — | — | — |
| 12 | Auralis UK-based generic pharma company | $2M | 194 mo ago | Deadpooled | Claude Nash CEO | 2005 | — | — | — |
| 13 | CoM3D Manufacturer of pharmaceuticals and 3D printing formulations | $1M | 71 mo ago | Seed | — | 2019 | — | — | — |
| 14 | RBT Manufacturer and seller of drugs | $115K | 103 mo ago | Funding Raised | Christine Brander Founder & CEO | 2008 | — | — | — |
Top 12 Traditional Pharmaceuticals companies in United Kingdom
#1
Series B · United Kingdom · founded 2020 · 10 employees$135.6Mraised▾
Manufacturer of drugs
- Oct 2024Series B$16.7M
- Apr 2024Series B$75M
- Nov 2020Series A$43.9M
#2
Acquired · Reading, England · founded 2004 · 23 employees$100Mraised▾
Archimedes Pharma Limited operates as a specialty pharmaceutical company. Its products include Gliadel, for high-grade glioma, Zomorph, an oral sustained release morphine product for cancer pain, Nozinan that treats nausea and vomiting in cancer patients, Pabrinex, a formulation of vitamins B and C for alcoholics experiencing acute withdrawal, and Nasalfent, intranasal fentanyl for the relief of cancer pain.
- Mar 2010Series C$97.6M
#3
Series C · Macclesfield, England · founded 2012 · 9 employees$11.6Mraised▾
Gelmetix develops gel-based, non-invasive, therapeutic biomaterial medical device. The device is meant to be an alternative to surgery. The company focuses on conditions such as chronic low back pain and osteoarthritis.
- May 2021Series C$7M
- 2020Grant (prize money)—
- Nov 2018Series B$3.9M
- 2015Seed$660K
#4
Acquired · London, England · founded 2006 · 41 employees$49Mraised▾
Specialty european pharma is engaged in the development of products for the treatment of urological conditions. It has its commercial operations in the UK, Germany, France, Italy and the Nordic region. Product brands marketed include bulkamid, mitocin, regurin, uraplex, and aquamid
- May 2016PE—
- Jan 2015Series B$5.6M
- Jul 2008Series B$23.9M
- Feb 2007Series A$19.4M
#5
Public · Chippenham, England · founded 1998 · 249 employees$45.1Mraised▾
International consumer healthcare business managing brands and partnerships. It operates by leveraging collaborations to maximize brand and business performance. The company supports its brands through various functions, including marketing, supply chain management, and scientific affairs. It fosters internal growth by providing opportunities for employee development and advancement. The business focuses on achieving growth for its shareholders through increased margins and strategic investments. A key aspect is the development and execution of a sustainability strategy.
- Jun 2018Post IPO$45.1M
#6
Acquired · Durham, England · founded 2004 · 218 employees$18.4Mraised▾
Manufacturer of unlicensed medicines
- Oct 2016Post IPO$18.4M
#7
Acquired · Durham, England · founded 2004$18.3Mraised▾
Manufacturer of drugs
- Oct 2016Post IPO$18.3M
#8
Series A · Newtown, Wales · founded 2005 · 1 employees$4.7Mraised▾
Provider of UK holiday park accommodations and ownership opportunities. It offers a variety of accommodation types, including caravans, lodges, and glamping options. The company also facilitates the sale of new and used holiday homes within its parks. Services include holiday bookings, touring and camping facilities, and support for holiday home owners. Additional amenities often include on-site activities, entertainment, and dining options. The business model centers on providing leisure accommodations and related services within a network of holiday parks.
- Dec 2009PE$640K
- Oct 2008Series A$2.2M
- Nov 2006Series A$1.9M
#9
Series A · Reading, England · founded 2017 · 9 employees$4.1Mraised▾
Marketer of branded prescription medicines for unmet needs. This company focuses on the marketing and distribution of branded prescription medications addressing underserved therapeutic areas. It builds strategic partnerships to expand its product portfolio and enhance market access. The company prioritizes providing quality medicines with added support at exceptional value to stakeholders. A commitment to sustainable business practices and ethical conduct guides its operations.
- Sep 2018Series A$4.1M
#10
Acquired · London, England · founded 2002 · 25 employees$4.4Mraised▾
Provider of geospatial data and aerial imagery services. This includes aerial photography, scan services for analog images, and aerotriangulation. They also create and process geospatial data, offering orthophotos, topographic maps, 3D terrain models derived from aerial or laser scan data, and 3D city models. Further services encompass specialized geospatial data such as green space inventories, property records with outdoor facilities, and solar potential analyses based on 3D models or laser scan data. WebGIS solutions for data visualization and analysis are also provided.
- Series A$4.4M
#11
Seed · Brighton, England · founded 2019 · 3 employees$1.2Mraised▾
Manufacturer of pharmaceuticals and 3D printing formulations
- Jun 2020Seed$1.2M
#12
Acquired · Cookham, England · founded 1999 · 13 employees$3.3Mraised▾
Intrapharm Laboratories is a speciality pharmaceutical focussed on the manufacturing and supply of OTC products to both the UK and Republic of Ireland. It has provided services for the supply of pharmaceutical products with proven therapeutic value and medical need addressing therapeutic areas covering oncology, ophthalmology, pain, gastrointestinal and dermatology. Its products include Lactulose Sachets, Terra Cortril, Carbocisteine Sachets, Triamcinolone Hexacetonide, Naltrexone Implants and Generics. In November 2015, Riemser Pharma acquired Intrapharm Laboratories.
- Sep 2014Conventional Debt—
- Aug 2014Series A$3.3M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Traditional Pharmaceuticals coverage by sub-theme.
Regulatory-risk over time flat
Funding & growth over time
funding rising · growth rising
How research on Drug Discovery is moving in the United Kingdom
A read on the academic research around Drug Discovery — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 2,687 United Kingdom-affiliated papers.
- University of Cambridge196
- University of Oxford176
- Imperial College London171
- AstraZeneca131
- University College London107
- Computational biology35→175
- Chemical space6→79
- Small molecule14→82
- High-throughput screening1→69
- Virtual screening4→67
- Computational biology43→197
- Pharmacology11→85
- In silico4→77
- Virtual screening10→66
- Docking (animal)8→63
- Drug development14→57
- Disease3→34
- Bioinformatics5→31
- Computational biology44→67
- Data science8→31
Where drug discovery is researched across United Kingdom
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing drug discovery patents in the United Kingdom
United Kingdom drug discovery patent filing is cooling — 70,971 filings from 8,000 assignees (2016–2025), led by Unilever, Glaxo Group, Glaxosmithkline IP DEV; annual filings 6378→5999.
- Unilever8136
- Glaxo Group7572
- Glaxosmithkline IP DEV3417
- Medimmune3098
- UCL Business2121
- Syngenta2073
- Astex Therapeutics1799
- Unilever Global IP1748
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.